Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Anthocyanin-rich Blackcurrant and Vascular Function

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
EstatiKonplete
Patwone
University of Reading
Kolaboratè
GlaxoSmithKline

Mo kle

Abstrè

Regular consumption of fruits and vegetables may improve human health and reduce the risk of chronic diseases, such as heart disease, certain cancers and type 2 diabetes, but the active components and the underlying mechanisms are poorly understood. Berry fruits are abundant in anthocyanins and this study aims to test the hypothesis that ingestion of an anthocyanin-rich blackcurrant beverage will improve markers of cardiovascular health (health of blood vessels, inflammation and platelet function). Further, the study will investigate the anthocyanin bioavailability from the blackcurrant beverage.

Dat

Dènye verifye: 01/31/2016
Premye Soumèt: 05/19/2015
Enskripsyon Estimasyon Soumèt: 05/31/2015
Premye afiche: 06/01/2015
Dènye Mizajou Soumèt: 02/07/2016
Dènye Mizajou afiche: 02/08/2016
Dat aktyèl kòmanse etid la: 05/31/2015
Dat Estimasyon Prensipal Estimasyon an: 10/31/2015
Dat estime fini etid la: 10/31/2015

Kondisyon oswa maladi

Vascular Stiffness
Inflammation

Entèvansyon / tretman

Other: Intervention

Other: Placebo

Faz

-

Gwoup bra

BraEntèvansyon / tretman
Active Comparator: Intervention
Spray dried blackcurrant powder dissolved in water
Other: Intervention
Placebo Comparator: Placebo
(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
Other: Placebo

Kritè kalifikasyon yo

Laj ki kalifye pou etid 30 Years Pou 30 Years
Sèks ki kalifye pou etidAll
Aksepte Volontè HealthyWi
Kritè

Inclusion Criteria:

- Aged 30-55 years

- Non-smoker

- BMI between 20 - 30 kg/m2

- Generally healthy as established by a 'health and lifestyle' questionnaire and a screening blood sample

- Blood pressure < 140/90mmHg

- Total cholesterol < 6.2 mmol/L

- Fasting glucose < 7.0 mmol/L

Exclusion Criteria:

- Diabetes mellitus

- Heart problems, stroke, vascular disease

- Inflammatory disease

- Kidney, liver, pancreas or gastrointestinal diseases

- Medication for hyperlipidaemia, hypertension, hypercoagulation, inflammatory conditions

- Asthma

- Allergies

- Smokers (social smokers who agree to abstain for 1 month before and during the study not excluded)

- Taking phytochemical, antioxidant or fish oil supplements (unless willing to stop for the study period)

- Taking aspirin > 2 times per month and unwilling to abstain from aspirin ingestion for 14 days prior each study visit

- History of alcohol misuse

- Consumption of alcohol >21 units (men) or >15 units (women)

- Vegans

- Intense aerobic exercise >20 min 3 x per week

- Participation in another clinical trial

- Antibiotics in previous 3 months before study

- Low haemoglobin levels

- Females who are pregnant, lactating, or if of reproductive age and not using a reliable form of contraception (including abstinence)

Rezilta

Mezi Rezilta Prensipal yo

1. Change from baseline in vascular reactivity measured by flow-mediated dilatation (FMD) [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention]

2. Change from baseline in platelet function measured by agonist-induced platelet aggregation [Acute study: measured at baseline and 2 and 4 h post intervention]

Mezi Rezilta Segondè

1. Change from baseline in the concentration of polyphenols and their metabolites and degradants in blood and urine samples measured by HPLC-MS/MS [Acute study: plasma measured at baseline and 1, 2, 4, 6 and 24 h post intervention, urine measured at baseline and 1, 2, 4, 6 and 6-24 h post intervention]

2. Change from baseline in vascular function measured by digital volume pulse (DVP) [Acute study: measured at baseline and 2, 4 and 6 h post intervention]

3. Change from baseline in blood pressure [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention]

4. Change from baseline in the concentration of nitric oxide in plasma measured by ozone-based chemiluminescence [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention]

5. Change from baseline in the concentration of selected cytokines (TNF-a, IL-1b, IL-6, IL-8 and IL-10) in plasma measured using a cytometric bead array kit from BD Biosciences [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention]

6. Change from baseline in platelet function (numbers of circulating micro particles by nano particle tracking analysis) [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention (urine metabonomics additionally 6-24h)]

7. Metabonomics on urine and plasma samples measured by nuclear magnetic resonance spectroscopy [Acute study: measured at baseline and 1, 2, 4 and 6 h post intervention (urine metabonomics additionally 6-24h)]

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge